uniQure makes milestone payment to Xenon for European approval of Glybera
The adeno-associated virus based human gene therapy Glybera developed by uniQure is indicated for the orphan disease lipoprotein lipase deficiency (LPLD). Xenon president and CEO Simon Pimstone said,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.